For years, Alzheimer’s research has focused on A-beta and tau amyloids, which harm neurons and impair brain function. A recent study from Johns Hopkins University suggests these plaques may not act alone. Researchers identified over…… 200 proteins under investigation...
At the European Academy of Neurology Congress in Helsinki, researchers unveiled a groundbreaking blood test that could revolutionize Alzheimer’s disease management by identifying patients with mild cognitive impairment (MCI) likely to progress rapidly to severe…… Ground-breaking Alzheimers blood test...
Two innovative Alzheimer’s drugs, donanemab and lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending independent living, by…… Donanemab and Lecanemab rejected for the NHS...